Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Drug Updates

Subcategories:AnalgesicsBiologics/DMARDs

Heparin Fails to Prevent Leg, Lung Clots After Arthroscopy, Casting

Gene Emery  |  

NEW YORK (Reuters Health)—Low-molecular-weight heparin failed to prevent symptomatic venous thromboemboli in people receiving knee arthroscopy or a lower leg cast, according to a pair of studies conducted in the Netherlands. The treatment is controversial because there is little clear evidence that heparin wards off clots in such instances. The research team, led by Dr. Raymond…

Teva Pharm to Market Medical Cannabis Inhaler in Israel

Reuters Staff  |  

JERUSALEM (Reuters)—Israel’s Teva Pharmaceuticals has partnered with Tel Aviv-based Syqe Medical to market in Israel medical cannabis for pain management that is administered with an inhaler. The companies said in a statement on Monday that this is the first time the medical cannabis sector has complied with pharmaceutical standards for inhalation, which is the most…

Transfer of Certolizumab in Breast Milk Not a Concern

Reuters Staff  |  

NEW YORK (Reuters Health)—There is minimal to no transfer of the tumor necrosis factor (TNF) inhibitor certolizumab (Cimzia) from plasma to breast milk, according to a new study. “These findings are reassuring” and imply that continuing certolizumab treatment is compatible with breastfeeding, Dr. Megan Clowse of Duke University School of Medicine in Durham, North Carolina,…

TNF Inhibitor Tied to Lower Cardiovascular Risk in Psoriasis

Lorraine L. Janeczko  |  

NEW YORK (Reuters Health)—Psoriasis patients treated with tumor necrosis factor-alpha (TNF) inhibitors may have a lower risk of major cardiovascular (CV) events than those treated with methotrexate (MTX), according to a new study. “The findings do not surprise me. TNF inhibitors control inflammation better than methotrexate,” lead author Dr. Jashin J. Wu of Kaiser Permanente…

Update on Legislation, Notification Rules Concerning the Substitution of Interchangeable Biologic Drugs

  |  

Although the FDA has not yet awarded the title of interchangeable to any biosimilar, legislation that governs their substitution will continue to be a dominant state issue in 2017. Since 2013, 24 states and Puerto Rico have passed legislation regarding interchangeable biologics. As many as 15 states will have biosimilar-related legislation introduced by coalitions in…